Comment Period Extended to 3/23/2015 for Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
67 studies found for:    S1007
Show Display Options
Rank Status Study
1 Recruiting Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients With Invasive RxPONDER Breast Cancer
Conditions: Estrogen Receptor Positive;   HER2/Neu Negative;   Progesterone Receptor Positive;   Stage II Breast Cancer;   Stage IIIA Breast Cancer;   Stage IIIB Breast Cancer;   Stage IIIC Breast Cancer
Interventions: Drug: Systemic Chemotherapy;   Drug: Tamoxifen Citrate;   Drug: Anastrozole;   Drug: Exemestane;   Drug: Letrozole;   Other: Laboratory Biomarker Analysis;   Other: Quality-of-Life Assessment
2 Completed Study to Evaluate the Safety and Efficacy of S-297995 for the Treatment of Opioid-Induced Bowel Dysfunction in Subjects With Chronic Pain
Condition: Opioid Induced Bowel Dysfunction
Interventions: Drug: 0.1 mg of S-297995 or placebo;   Drug: 0.3 mg of S-297995 or placebo;   Drug: 1 mg of S-297995 or placebo;   Drug: 3 mg of S-297995 or placebo;   Drug: 0.03 mg of S-297995 or placebo;   Drug: 0.01 mg of S-297995 or placebo
3 Completed A Study of 5-FUci Versus CPT-11 Plus CDDP Versus S-1 Alone in Advanced Gastric Cancer
Condition: Gastric Cancer
Interventions: Drug: continuous infusion of 5-fluorouracil;   Drug: combination of irinotecan and cisplatin;   Drug: oral administration of S-1
4 Recruiting S1216, Phase III ADT+TAK-700 vs. ADT+Bicalutamide for Metastatic Prostate Cancer
Condition: Prostate Cancer
Interventions: Drug: TAK-700;   Drug: Bicalutamide
5 Recruiting S0931, Everolimus in Treating Patients With Kidney Cancer Who Have Undergone Surgery
Condition: Kidney Cancer
Interventions: Drug: everolimus;   Other: placebo
6 Completed
Has Results
"REDUCE" - A Clinical Research Study To Reduce The Incidence Of Prostate Cancer In Men Who Are At Increased Risk
Condition: Neoplasms, Prostate
Interventions: Drug: Dutasteride;   Drug: Placebo
7 Recruiting S1011 Standard or Extended Pelvic Lymphadenectomy in Treating Patients Undergoing Surgery for Invasive Bladder Cancer
Condition: Bladder Cancer
Interventions: Procedure: therapeutic conventional surgery;   Procedure: therapeutic lymphadenectomy
8 Recruiting (C2013-0302) Safety and Efficacy of Escalating Doses of SAN-300 in Patients With Rheumatoid Arthritis
Condition: Rheumatoid Arthritis
Interventions: Drug: SAN-300;   Drug: Placebo
9 Active, not recruiting Sientra Post-Approval Study
Conditions: Breast Augmentation;   Breast Reconstruction;   Breast Revision
10 Completed Safety and Efficacy of Inhaled Insulin in Patients With Diabetes and Asthma or COPD
Conditions: Diabetes Mellitus;   Asthma;   Pulmonary Disease, Chronic Obstructive
Interventions: Drug: Human Insulin Inhalation Powder;   Drug: injected insulin
11 Active, not recruiting Alemtuzumab and CHOP in T-cell Lymphoma
Condition: Lymphoma, T-Cell, Peripheral
Interventions: Drug: CHOP14 chemotherapy (cyclophosphamide, hydroxydaunorubicin, vincristin, prednison) plus G-CSF, combined with alemtuzumab;   Drug: CHOP14 chemotherapy (see specification under Arm B) plus G-CSF
12 Recruiting Open-label Extension and Safety Study for Patients With Ulcerative Colitis Previously Enrolled in Etrolizumab Phase III Studies
Condition: Ulcerative Colitis
Intervention: Drug: etrolizumab
13 Completed Study of Immunotherapy to Treat Advanced Prostate Cancer
Condition: Prostate Cancer
Interventions: Drug: Ipilimumab;   Drug: Placebo
14 Completed Bioequivalence of NovoSeven® and a NovoSeven® Formulation Stable at Room Temperature in Healthy Male Subjects
Conditions: Acquired Bleeding Disorder;   Acquired Haemophilia;   Congenital Bleeding Disorder;   Congenital FVII Deficiency;   Glanzmann's Disease;   Haemophilia A With Inhibitors;   Haemophilia B With Inhibitors;   Healthy
Intervention: Drug: activated recombinant human factor VII
15 Completed LAS41005 in Hyperkeratotic Actinic Keratosis
Condition: Hyperkeratotic Actinic Keratosis
Interventions: Procedure: Cryotherapy;   Drug: LAS41005
16 Completed Tolerability and Pharmacokinetics of Metformin and Metformin Extended Release (ER)
Condition: Healthy
Interventions: Drug: metformin ER;   Drug: metformin
17 Recruiting A Study of GDC-0199 (ABT-199) Plus MabThera/Rituxan (Rituximab) Compared With Bendamustine Plus MabThera/Rituxan (Rituximab) in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia
Condition: Chronic Lymphocytic Leukemia
Interventions: Drug: Bendamustine;   Drug: GDC-0199;   Drug: Rituximab [MabThera/Rituxan]
18 Recruiting A Study Comparing the Efficacy and Safety of Etrolizumab to Infliximab in Patients With Moderate to Severe Ulcerative Colitis Who Are Naive to TNF Inhibitors
Condition: Ulcerative Colitis
Interventions: Drug: etrolizumab;   Drug: infliximab;   Other: placebo (IV);   Other: placebo (injection)
19 Recruiting A Study of the Efficacy and Safety of Etrolizumab in Ulcerative Colitis Patients Who Are Refractory to or Intolerant of TNF Inhibitors
Condition: Ulcerative Colitis
Interventions: Drug: etrozulimab;   Drug: placebo
20 Completed ACT-128800 in Patients With Moderate to Severe Chronic Plaque Psoriasis
Condition: Psoriasis
Interventions: Drug: ACT-128800;   Drug: Placebo

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Indicates status has not been verified in more than two years